Adenine

Adenine

SCHEMBL1065182

Nc1cc[nH]c(=O)n1.Nc1ncnc2[nH]cnc12

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.41
PI4KA P42356 2/20 0.34
PI4K2B Q8TCG2 2/20 0.34
PI4K2A Q9BTU6 2/20 0.34
PI4KB Q9UBF8 2/20 0.34
LMNA P02545 1/20 0.34
DRD3 P35462 1/20 0.34
XDH P47989 1/20 0.34
LRRK2 Q5S007 1/20 0.34
PNP P00491 1/20 0.34
PARP1 P09874 1/20 0.33
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenine SCHEMBL19974438 1.00 MAP4K4 (0.41) MAP4K4PI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL4579285 1.00 MAP4K4 (0.41) MAP4K4PI4KAPI4K2BPI4K2API4KB
Guanine SCHEMBL1730016 0.89 DYRK1A (0.42) MAP4K4LMNAXDHPNPPARP1
Adenine SCHEMBL4579096 0.85 ATAD2 (0.41) MAP4K4PNPPARP1
2,6-Diaminopurine SCHEMBL23292803 0.84 DYRK1A (0.38) MAP4K4LMNAPNPDYRK1A
Guanine SCHEMBL2636585 0.82 KDM4E (0.38) MAP4K4LMNAPNPDYRK1A
Cytosine SCHEMBL15271432 0.81 PNP (0.32) MAP4K4LRRK2PNPPARP1DYRK1A
Adenine SCHEMBL6227731 0.80 ATAD2 (0.37) MAP4K4
Adenine SCHEMBL3416954 0.80 PI4KA (0.48) MAP4K4PI4KAPI4K2BPI4K2API4KB
Adenine SCHEMBL3414603 0.80 PI4KA (0.48) MAP4K4PI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115287272-A Novel dye decoloring method for clone and recombinase of DyP-type peroxidase gene 浙江省农业科学院 2022-11-04 CN claimed
EP-3512860-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB Pharma Inc. (CA) 2019-07-24 EP claimed
US-20180208924-A1 METHOD FOR INTRODUCING SITE-DIRECTED RNA MUTATION, TARGET EDITING GUIDE RNA USED IN THE METHOD AND TARGET RNA-TARGET EDITING GUIDE RNA COMPLEX FUKUOKA UNIVERSITY (JP) 2018-07-26 US claimed
WO-2018049534-A1 NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT LCB PHARMA INC. (CA) 2018-03-22 WO claimed
WO-2024145248-A1 COMPOSITIONS AND METHODS FOR GENERATING CIRCULAR RNA LEVATIO THERAPEUTICS, LLC (US) 2024-07-04 WO disclosed
CN-115287272-A Novel dye decoloring method for clone and recombinase of DyP-type peroxidase gene 浙江省农业科学院 2022-11-04 CN disclosed
US-11279736-B2 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids CARNEGIE MELLON UNIVERSITY (US) 2022-03-22 US disclosed
US-20210214397-A1 CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS CARNEGIE MELLON UNIVERSITY (US) 2021-07-15 US disclosed
CN-110430897-B Conjugation unit and molecular construct comprising same 免疫功坊股份有限公司 2021-01-22 CN disclosed
US-20200364229-A1 PARALLELIZABLE SEQUENCE ALIGNMENT SYSTEMS AND METHODS SAMSUNG ELECTRONICS CO LTD (KR) 2020-11-19 US disclosed
CN-111867626-A Methods and compositions for treating amyloid deposition diseases 纽约哥伦比亚大学理事会 2020-10-30 CN disclosed
EP-2558496-B1 ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE GENENTECH INC (US) 2018-07-25 EP disclosed
WO-2007103814-A2 ANGIOGENESIS PATHWAY GENE POLYMORPHISMS FOR THERAPY SELECTION UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2007-09-13 WO disclosed
US-20070207486-A1 determining whether a patient will respond to anti-VEGF antibody based chemotherapy by screening suitable cell or tissue sample from the patient for at least one genomic polymorphism or genotype; using a bevacizumab antibody or an antibody that binds to the same epitope on VEGF and and cyclophosphamide UNIVERSITY OF SOUTHERN CALIFORNIA 2007-09-06 US disclosed
CN-1753687-A Use of cpg oligonucleotides in the treatment of hepatitis c virus infection COLEY PHARMACEUTICAL GROUP LTD (CA) 2006-03-29 CN disclosed
EP-1005478-A1 RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR PREPARING THE SAME Pitsch, Stefan (CH) 2000-06-07 EP disclosed
WO-1999009044-A1 RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR PREPARING THE SAME PITSCH STEFAN (CH) 1999-02-25 WO disclosed
US-5780607-A PYRANOSYL NUCLEOSIDE MONOMER UNITS CONNECTED BY AMIDE LINKAGES HOFFMANN-LA ROCHE INC. (US) 1998-07-14 US disclosed
US-5730940-A DETECTION DNA BASE ARRANGEMENT MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1998-03-24 US disclosed
US-4997818-A Using a nitrogenous heterocyclic base and dideoxy-pentose monosaccharides THE UNIVERSITY HOSPITAL (US) 1991-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279736-B2 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids POLL, PCNA, POLG MAP4K4 4637/4885PI4KA 1915/4885PI4K2B 2188/4885
US-20210214397-A1 CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS POLL, PCNA, POLG MAP4K4 4637/4885PI4KA 1915/4885PI4K2B 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.